<DOC>
	<DOCNO>NCT00545714</DOCNO>
	<brief_summary>This single arm study ass efficacy safety rituximab combination fludarabine cyclophosphamide , follow rituximab maintenance therapy , first line treatment participant CLL .</brief_summary>
	<brief_title>A Study Assess Efficacy Rituximab ( MabThera ) First Line Treatment Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Cluster Differentiation ( CD ) 20positive Bcell CLL Active disease No previous treatment Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Transformation aggressive Bcell malignancy ( prolymphocytic leukemia , largecell lymphoma , Hodgkin 's lymphoma ) Other malignancy except localized skin cancer Continuous systemic corticosteroid treatment Known infection hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>